Insulet Corp demonstrated robust fiscal 2025 growth, with revenues up 30.7% to $2.71 billion driven by its Omnipod platform's expanding adoption domestically and internationally. Operating income surged 53.4% to $474 million, while net income declined 40.9% due to nonrecurring debt extinguishment costs. Strategic investments in automated manufacturing capacity, including a new Costa Rica facility, underpin long-term operational leverage. Capital structure optimization included debt refinancing and interest rate hedging, reducing leverage to a 39% debt-to-capital ratio. The company returned $59.6 million in share repurchases under an extended buyback program, maintaining a no-dividend policy. Risks involve sole-source component dependency and competitive pressures in diabetes care markets.